Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 51.97
SCLN's Cash to Debt is ranked higher than
78% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. SCLN: 51.97 )
SCLN' s 10-Year Cash to Debt Range
Min: 2.83   Max: No Debt
Current: 51.97

Equity to Asset 0.81
SCLN's Equity to Asset is ranked higher than
85% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. SCLN: 0.81 )
SCLN' s 10-Year Equity to Asset Range
Min: 0.62   Max: 0.94
Current: 0.81

0.62
0.94
Interest Coverage 101.25
SCLN's Interest Coverage is ranked higher than
67% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 90.51 vs. SCLN: 101.25 )
SCLN' s 10-Year Interest Coverage Range
Min: 34.65   Max: 9999.99
Current: 101.25

34.65
9999.99
F-Score: 5
Z-Score: 4.65
M-Score: -2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.21
SCLN's Operating margin (%) is ranked higher than
71% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. SCLN: 8.21 )
SCLN' s 10-Year Operating margin (%) Range
Min: -17400   Max: 26.31
Current: 8.21

-17400
26.31
Net-margin (%) 8.63
SCLN's Net-margin (%) is ranked higher than
75% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. SCLN: 8.63 )
SCLN' s 10-Year Net-margin (%) Range
Min: -17900   Max: 24.77
Current: 8.63

-17900
24.77
ROE (%) 7.48
SCLN's ROE (%) is ranked higher than
73% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SCLN: 7.48 )
SCLN' s 10-Year ROE (%) Range
Min: -293.06   Max: 25.65
Current: 7.48

-293.06
25.65
ROA (%) 6.08
SCLN's ROA (%) is ranked higher than
81% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.95 vs. SCLN: 6.08 )
SCLN' s 10-Year ROA (%) Range
Min: -180.34   Max: 21.55
Current: 6.08

-180.34
21.55
ROC (Joel Greenblatt) (%) 39.33
SCLN's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.63 vs. SCLN: 39.33 )
SCLN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2257.14   Max: 96.28
Current: 39.33

-2257.14
96.28
Revenue Growth (%) 10.30
SCLN's Revenue Growth (%) is ranked higher than
74% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SCLN: 10.30 )
SCLN' s 10-Year Revenue Growth (%) Range
Min: -4.7   Max: 135.1
Current: 10.3

-4.7
135.1
EBITDA Growth (%) -19.00
SCLN's EBITDA Growth (%) is ranked higher than
51% of the 504 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.00 vs. SCLN: -19.00 )
SCLN' s 10-Year EBITDA Growth (%) Range
Min: -53.8   Max: 13.5
Current: -19

-53.8
13.5
EPS Growth (%) -22.50
SCLN's EPS Growth (%) is ranked higher than
54% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. SCLN: -22.50 )
SCLN' s 10-Year EPS Growth (%) Range
Min: -58.7   Max: 132.1
Current: -22.5

-58.7
132.1
» SCLN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SCLN Guru Trades in Q1 2013

Chuck Royce 11,700 sh (unchged)
Steven Cohen Sold Out
Jim Simons 14,430 sh (-31.05%)
Paul Tudor Jones 63,800 sh (-38.42%)
» More
Q2 2013

SCLN Guru Trades in Q2 2013

Jim Simons 135,800 sh (+841.09%)
Chuck Royce 11,700 sh (unchged)
Paul Tudor Jones 25,800 sh (-59.56%)
» More
Q3 2013

SCLN Guru Trades in Q3 2013

Steven Cohen 22,664 sh (New)
Jim Simons 506,100 sh (+272.68%)
Chuck Royce 13,700 sh (+17.09%)
Paul Tudor Jones 28,100 sh (+8.91%)
» More
Q4 2013

SCLN Guru Trades in Q4 2013

John Burbank 13,513 sh (New)
Paul Tudor Jones 35,700 sh (+27.05%)
Chuck Royce 13,700 sh (unchged)
Steven Cohen Sold Out
Jim Simons 234,904 sh (-53.59%)
» More
» Details

Insider Trades

Latest Guru Trades with SCLN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-12-31 New Buy$4.37 - $5.26 $ 4.47-7%13513
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.90
SCLN's P/E(ttm) is ranked higher than
74% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. SCLN: 21.90 )
SCLN' s 10-Year P/E(ttm) Range
Min: 6.29   Max: 189.41
Current: 21.9

6.29
189.41
P/B 1.60
SCLN's P/B is ranked higher than
81% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. SCLN: 1.60 )
SCLN' s 10-Year P/B Range
Min: 0.82   Max: 11.85
Current: 1.6

0.82
11.85
P/S 1.90
SCLN's P/S is ranked higher than
73% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. SCLN: 1.90 )
SCLN' s 10-Year P/S Range
Min: 0.67   Max: 12.41
Current: 1.9

0.67
12.41
PFCF 28.10
SCLN's PFCF is ranked higher than
62% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.79 vs. SCLN: 28.10 )
SCLN' s 10-Year PFCF Range
Min: 3.83   Max: 458
Current: 28.1

3.83
458
EV-to-EBIT 14.10
SCLN's EV-to-EBIT is ranked higher than
75% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. SCLN: 14.10 )
SCLN' s 10-Year EV-to-EBIT Range
Min: 0.2   Max: 207.3
Current: 14.1

0.2
207.3
Shiller P/E 18.20
SCLN's Shiller P/E is ranked higher than
79% of the 363 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. SCLN: 18.20 )
SCLN' s 10-Year Shiller P/E Range
Min: 17.36   Max: 218.5
Current: 18.2

17.36
218.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.60
SCLN's Price/Net Cash is ranked higher than
84% of the 219 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.70 vs. SCLN: 4.60 )
SCLN' s 10-Year Price/Net Cash Range
Min: 2.06   Max: 343.8
Current: 4.6

2.06
343.8
Price/Net Current Asset Value 2.60
SCLN's Price/Net Current Asset Value is ranked higher than
90% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. SCLN: 2.60 )
SCLN' s 10-Year Price/Net Current Asset Value Range
Min: 1.19   Max: 160
Current: 2.6

1.19
160
Price/Tangible Book 2.10
SCLN's Price/Tangible Book is ranked higher than
75% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. SCLN: 2.10 )
SCLN' s 10-Year Price/Tangible Book Range
Min: 0.84   Max: 13.92
Current: 2.1

0.84
13.92
Price/DCF (Projected) 0.70
SCLN's Price/DCF (Projected) is ranked higher than
96% of the 349 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. SCLN: 0.70 )
SCLN' s 10-Year Price/DCF (Projected) Range
Min: 0.78   Max: 3.1
Current: 0.7

0.78
3.1
Price/Median PS Value 0.80
SCLN's Price/Median PS Value is ranked higher than
87% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. SCLN: 0.80 )
SCLN' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 84.38
Current: 0.8

0.25
84.38
Price/Graham Number 1.40
SCLN's Price/Graham Number is ranked higher than
74% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. SCLN: 1.40 )
SCLN' s 10-Year Price/Graham Number Range
Min: 0.89   Max: 4.95
Current: 1.4

0.89
4.95
Earnings Yield (Greenblatt) 7.10
SCLN's Earnings Yield (Greenblatt) is ranked higher than
79% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. SCLN: 7.10 )
SCLN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 482.2
Current: 7.1

0.5
482.2
Forward Rate of Return (Yacktman) 5.86
SCLN's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. SCLN: 5.86 )
SCLN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -20.8   Max: 7.1
Current: 5.86

-20.8
7.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:SPJ.Germany
SciClone Pharmaceuticals, Inc., a Delaware corporation was incorporated in 1990. The Company is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. The Company's primary product, ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. It markets approximately 14 partnered products in China, including Depakine, a prescribed broad-spectrum anti-convulsant in China; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien in the US); and Aggrastat, an interventional cardiology product. The Company operates is two segments based on the nature and locations of its customers: China and the rest of the world which includes its US and Hong Kong operations. It competitors for existing and future products include pharmaceutical companies, biotechnology firms, universities and other research institutions, in the US, China and other territories, that are actively engaged in research and development or marketing of products in the therapeutic areas the Company is pursuing. The Company's products in clinical development in the US, China and other foreign countries are subject to approval by the FDA, the SFDA and similar regulatory authorities.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide